amifostine anhydrous has been researched along with Stomatitis in 41 studies
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.
Stomatitis: INFLAMMATION of the soft tissues of the MOUTH, such as MUCOSA; PALATE; GINGIVA; and LIP.
| Excerpt | Relevance | Reference |
|---|---|---|
| "High-dose melphalan (HDM) has been adopted as standard therapy in the treatment of multiple myeloma." | 9.10 | Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma. ( Arnaud, P; Bouafia, F; Coiffier, B; Du Manoir-Baumgarten, C; Dumontet, C; Eljaafari-Corbin, A; Espinouse, D; Hequet, O; Roch, N; Roy, P; Saad, H; Salles, G; Thieblemont, C, 2002) |
| "High-dose melphalan (HDM) has been adopted as standard therapy in the treatment of multiple myeloma." | 5.10 | Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma. ( Arnaud, P; Bouafia, F; Coiffier, B; Du Manoir-Baumgarten, C; Dumontet, C; Eljaafari-Corbin, A; Espinouse, D; Hequet, O; Roch, N; Roy, P; Saad, H; Salles, G; Thieblemont, C, 2002) |
| "The treatment of head and neck cancer continues to evolve." | 2.71 | Phase II randomized study of concomitant chemoradiation using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with newly diagnosed locally advanced squamous cell carcinoma of the head and neck. ( Costello, R; Haddad, R; Posner, M; Weeks, L; Wirth, L, 2003) |
| " This is the first report focusing on amifostine related adverse effects leading to discontinuation of amifostine treatment." | 2.71 | Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients. ( Alberti, W; Bajrovic, A; Fehlauer, F; Mahlmann, B; Rades, D; Richter, E, 2004) |
| "Also grade III or IV infections (P=0." | 2.71 | A randomized trial of amifostine as a cytoprotectant for patients receiving myeloablative therapy for allogeneic hematopoietic stem cell transplantation. ( Chow, H; Chuah, CT; Fook, SC; Goh, YT; Hwang, WY; Koh, LP; Ng, HJ; Tan, CH; Tan, KW; Tan, PH; Wong, C, 2004) |
| "Hypotension was the most important adverse event of AMI infusion." | 2.70 | A pilot study on feasibility and efficacy of amifostine preceding high-dose melphalan with autologous stem cell support in myeloma patients. ( Jantunen, E; Kuittinen, T; Nousiainen, T, 2002) |
| "Twenty-three patients with advanced head and neck cancer, mainly Stage III and IV, were treated with preoperative radiation (n = 1), pre- as well as postoperative radiotherapy (n = 5), postoperative radiation (n = 9) or combined postoperative radio-chemotherapy (n = 6)." | 2.69 | [Cytoprotection with amifostine in radiotherapy or radio-chemotherapy of head and neck tumors]. ( Altmann, S; Hoffmanns, H, 1999) |
| "Radiotherapy for head and neck cancer causes acute and chronic xerostomia and acute mucositis." | 2.69 | Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. ( Brizel, DM; Eschwege, F; Henke, M; Monnier, A; Oster, W; Rudat, V; Russell, L; Sauer, R; Strnad, V; Wasserman, TH; Zhang, J, 2000) |
| "Oral mucositis is a common complication of cancer treatment that may negatively impact the patient's cancer treatment outcome." | 2.52 | Mucositis: pathobiology and management. ( Sonis, ST; Villa, A, 2015) |
| "Mucositis is a highly significant, and sometimes dose-limiting, toxicity of cancer therapy." | 2.50 | MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. ( Barasch, A; Bowen, J; Elad, S; Elting, L; Epstein, J; Keefe, DM; Lalla, RV; McGuire, DB; Migliorati, C; Nicolatou-Galitis, O; Peterson, DE; Raber-Durlacher, JE; Sonis, ST, 2014) |
| "radiotherapy plus amifostine for cancer treatment." | 2.43 | Amifostine reduces side effects and improves complete response rate during radiotherapy: results of a meta-analysis. ( Clark, LG; Clark, OA; Sasse, AD; Sasse, EC, 2006) |
| "Mucositis is a significant complication of cancer therapy, with important clinical and economic implications." | 2.43 | Amifostine in the management of radiation-induced and chemo-induced mucositis. ( Bensadoun, RJ; Keefe, D; Lalla, RV; Schubert, MM, 2006) |
| "Mucositis was scored by either the WHO, the National Cancer Institute-Common Toxicity Criteria (NCI-CTC) score, or the absence or presence of ulcerations, or the presence or absence of grades 3 and 4 mucositis." | 2.43 | Preventive intervention possibilities in radiotherapy- and chemotherapy-induced oral mucositis: results of meta-analyses. ( Boezen, HM; de Vries, EG; Roodenburg, JL; Schouten, JP; Spijkervet, FK; Stokman, MA, 2006) |
| "Radiodermatitis and radioinduced oral mucositis are frequent and significant side effects among patients with breast and head and neck cancer, respectively." | 1.51 | Preventing Radiation-Induced Injury by Topical Application of an Amifostine Metabolite-Loaded Thermogel. ( Benel, L; Bloy, C; Bricout, D; Chargari, C; Clémenson, C; Deutsch, E; Haddad, R; Liu, W; Mondini, M; Soyez-Herkert, L; Wang-Zhang, X, 2019) |
| "We focused on the relationship between oral mucositis and keratinocyte injury and examined methotrexate and 5-fluorouracil-induced cytotoxicity in normal human epidermal keratinocyte cell lines." | 1.35 | Protective effects of amifostine and cyclooxygenase-1 inhibitor against normal human epidermal keratinocyte toxicity induced by methotrexate and 5-fluorouracil. ( Kaji, H; Maiguma, T; Makino, K; Teshima, D, 2009) |
| "Oral mucositis is a common side effect induced by radio/chemotherapy in patients with head and neck cancer." | 1.35 | Differential effect triggered by a heparan mimetic of the RGTA family preventing oral mucositis without tumor protection. ( Auperin, A; Barritault, D; Biti, G; Bourhis, J; Castaing, M; Deutsch, E; Frascogna, V; Mangoni, M; Morin, C; Opolon, P; Tao, Y; Violot, D; Vozenin-Brotons, MC; Yue, X, 2009) |
| "A total of 117 cancer patients with carcinomas localized in pelvic organs, lung and head and neck were entered into this study." | 1.31 | Cytoprotective effect of amifostine in radiation-induced acute mucositis - a retrospective analysis. ( Balafouta, M; Kokakis, J; Kouloulias, V; Kouvaris, J; Matsopoulos, G; Miliadou, A; Vlahos, L, 2002) |
| "Chemoradiation induced oral mucositis was delayed and showed significant lower degrees at all 10 Gy increments (p < 0." | 1.30 | Daily amifostine given concomitantly to chemoradiation in head and neck cancer. A pilot study. ( Bank, P; Beleites, E; Koscielny, S; Trog, D; Wendt, TG, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (12.20) | 18.2507 |
| 2000's | 30 (73.17) | 29.6817 |
| 2010's | 6 (14.63) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barbosa, SCM | 1 |
| Pereira, VBM | 1 |
| Wong, DVT | 1 |
| Santana, APM | 1 |
| Lucetti, LT | 1 |
| Carvalho, LL | 1 |
| Barbosa, CRN | 1 |
| Callado, RB | 1 |
| Silva, CAA | 1 |
| Lopes, CDH | 1 |
| Brito, GAC | 1 |
| Alencar, NMN | 1 |
| Lima-Júnior, RCP | 1 |
| Clémenson, C | 1 |
| Liu, W | 1 |
| Bricout, D | 1 |
| Soyez-Herkert, L | 1 |
| Chargari, C | 1 |
| Mondini, M | 1 |
| Haddad, R | 3 |
| Wang-Zhang, X | 1 |
| Benel, L | 1 |
| Bloy, C | 1 |
| Deutsch, E | 3 |
| Lalla, RV | 3 |
| Bowen, J | 2 |
| Barasch, A | 1 |
| Elting, L | 1 |
| Epstein, J | 1 |
| Keefe, DM | 1 |
| McGuire, DB | 1 |
| Migliorati, C | 1 |
| Nicolatou-Galitis, O | 2 |
| Peterson, DE | 1 |
| Raber-Durlacher, JE | 1 |
| Sonis, ST | 2 |
| Elad, S | 2 |
| Li, CJ | 1 |
| Wang, SZ | 1 |
| Wang, SY | 1 |
| Zhang, YP | 1 |
| Villa, A | 1 |
| Rosenthal, DI | 1 |
| Trotti, A | 1 |
| Maiguma, T | 1 |
| Kaji, H | 1 |
| Makino, K | 1 |
| Teshima, D | 1 |
| Mangoni, M | 1 |
| Yue, X | 1 |
| Morin, C | 1 |
| Violot, D | 1 |
| Frascogna, V | 1 |
| Tao, Y | 1 |
| Opolon, P | 1 |
| Castaing, M | 1 |
| Auperin, A | 1 |
| Biti, G | 1 |
| Barritault, D | 1 |
| Vozenin-Brotons, MC | 1 |
| Bourhis, J | 2 |
| Sonis, S | 1 |
| Posner, M | 2 |
| Wirth, L | 2 |
| Costello, R | 2 |
| Braschayko, P | 1 |
| Allen, A | 1 |
| Mahadevan, A | 1 |
| Flynn, J | 1 |
| Burke, E | 1 |
| Li, Y | 1 |
| Tishler, RB | 1 |
| Sarri, T | 1 |
| Di Palma, M | 1 |
| Kouloulias, VE | 1 |
| Niscola, P | 1 |
| Riesenbeck, D | 1 |
| Stokman, M | 1 |
| Tissing, W | 1 |
| Yeoh, E | 1 |
| Kouvaris, J | 1 |
| Kouloulias, V | 1 |
| Kokakis, J | 1 |
| Matsopoulos, G | 1 |
| Balafouta, M | 1 |
| Miliadou, A | 1 |
| Vlahos, L | 1 |
| Thieblemont, C | 1 |
| Dumontet, C | 1 |
| Saad, H | 1 |
| Roch, N | 1 |
| Bouafia, F | 1 |
| Arnaud, P | 1 |
| Hequet, O | 1 |
| Espinouse, D | 1 |
| Salles, G | 1 |
| Roy, P | 1 |
| Eljaafari-Corbin, A | 1 |
| Du Manoir-Baumgarten, C | 1 |
| Coiffier, B | 1 |
| Jantunen, E | 1 |
| Kuittinen, T | 1 |
| Nousiainen, T | 1 |
| Lorusso, D | 1 |
| Ferrandina, G | 1 |
| Greggi, S | 1 |
| Gadducci, A | 1 |
| Pignata, S | 1 |
| Tateo, S | 1 |
| Biamonte, R | 1 |
| Manzione, L | 1 |
| Di Vagno, G | 1 |
| Ferrau', F | 1 |
| Scambia, G | 1 |
| Antonadou, D | 2 |
| Throuvalas, N | 2 |
| Petridis, A | 1 |
| Bolanos, N | 1 |
| Sagriotis, A | 1 |
| Synodinou, M | 2 |
| Cassatt, DR | 3 |
| Fazenbaker, CA | 3 |
| Kifle, G | 2 |
| Bachy, CM | 3 |
| Hu, K | 1 |
| Ship, JA | 1 |
| Harrison, LB | 1 |
| Gabriel, DA | 1 |
| Shea, T | 1 |
| Olajida, O | 1 |
| Serody, JS | 1 |
| Comeau, T | 1 |
| Weeks, L | 1 |
| Rades, D | 1 |
| Fehlauer, F | 1 |
| Bajrovic, A | 1 |
| Mahlmann, B | 1 |
| Richter, E | 2 |
| Alberti, W | 1 |
| Hwang, WY | 1 |
| Koh, LP | 1 |
| Ng, HJ | 1 |
| Tan, PH | 1 |
| Chuah, CT | 1 |
| Fook, SC | 1 |
| Chow, H | 1 |
| Tan, KW | 1 |
| Wong, C | 1 |
| Tan, CH | 1 |
| Goh, YT | 1 |
| McCarthy, MP | 1 |
| Spencer, A | 1 |
| Horvath, N | 1 |
| Gibson, J | 1 |
| Prince, HM | 1 |
| Herrmann, R | 1 |
| Bashford, J | 1 |
| Joske, D | 1 |
| Grigg, A | 1 |
| McKendrick, J | 1 |
| Prosser, I | 1 |
| Lowenthal, R | 1 |
| Deveridge, S | 1 |
| Taylor, K | 1 |
| Sasse, AD | 1 |
| Clark, LG | 1 |
| Sasse, EC | 1 |
| Clark, OA | 1 |
| Buentzel, J | 1 |
| Micke, O | 1 |
| Adamietz, IA | 1 |
| Monnier, A | 2 |
| Glatzel, M | 2 |
| de Vries, A | 1 |
| Bensadoun, RJ | 1 |
| Schubert, MM | 1 |
| Keefe, D | 1 |
| Stokman, MA | 1 |
| Spijkervet, FK | 1 |
| Boezen, HM | 1 |
| Schouten, JP | 1 |
| Roodenburg, JL | 1 |
| de Vries, EG | 1 |
| Fleischer, G | 1 |
| Dörr, W | 1 |
| Trog, D | 1 |
| Bank, P | 1 |
| Wendt, TG | 1 |
| Koscielny, S | 1 |
| Beleites, E | 1 |
| Sauer, R | 2 |
| Strnad, V | 2 |
| Vacha, P | 1 |
| Marx, M | 1 |
| Engel, A | 1 |
| Feyerabend, T | 1 |
| Altmann, S | 1 |
| Hoffmanns, H | 1 |
| Büntzel, J | 1 |
| Schuth, J | 1 |
| Weinaug, R | 1 |
| Küttner, K | 1 |
| Fröhlich, D | 1 |
| De Crevoisier, R | 1 |
| Abdulkarim, B | 1 |
| Lusinchi, A | 1 |
| Luboinski, B | 1 |
| Wibault, P | 1 |
| Eschwege, F | 2 |
| Capelli, D | 1 |
| Santini, G | 1 |
| De Souza, C | 1 |
| Poloni, A | 1 |
| Marino, G | 1 |
| Montanari, M | 1 |
| Lucesole, M | 1 |
| Brunori, M | 1 |
| Massidda, D | 1 |
| Offidani, M | 1 |
| Leoni, P | 1 |
| Olivieri, A | 1 |
| Brizel, DM | 1 |
| Wasserman, TH | 1 |
| Henke, M | 1 |
| Rudat, V | 1 |
| Zhang, J | 1 |
| Russell, L | 1 |
| Oster, W | 1 |
| Noël, G | 1 |
| Mazeron, JJ | 1 |
| Pepelassi, M | 1 |
| Puglisi, M | 1 |
| Hanson, MS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Single Center, Open Label Clinical Investigation on the Treatment of Radiation Induced Dermatitis With Radiation Care® Gel[NCT04995328] | 23 participants (Actual) | Interventional | 2021-08-03 | Completed | |||
| A Randomized Study of a New Medical Device for Oral Mucositis (MDOM Trial)[NCT05104268] | Phase 1/Phase 2 | 100 participants (Anticipated) | Interventional | 2021-11-30 | Not yet recruiting | ||
| Low Power Laser Therapy As Prevention Of Oral Mucositis And Oropharyngeal Pain In Patients Undergoing Allogenetic Hematopoietic Stem Cell Transplantation.[NCT06071637] | Phase 3 | 84 participants (Anticipated) | Interventional | 2023-08-01 | Recruiting | ||
| Cryoprotection of Chemotherapy-induced Oral Mucositis After Autologous Stem Cell Transplantation, a Randomized Study[NCT03203733] | 182 participants (Actual) | Interventional | 2017-06-12 | Completed | |||
| A Phase 1/Phase 2 Study for the Prevention of Oral Mucositis (SPOM)[NCT05338398] | Phase 1/Phase 2 | 100 participants (Anticipated) | Interventional | 2022-04-15 | Enrolling by invitation | ||
| Opioid Therapy vs Multimodal Analgesia in Head and Neck Cancer: A Randomized Clinical Trial[NCT04221165] | Phase 2 | 62 participants (Anticipated) | Interventional | 2020-08-04 | Recruiting | ||
| Phase I Study of Multiple Ascending Dose, to Investigate the Safety and Tolerability of the Use of Copaiba in Patients With Oral Cancer Submitted to Radiotherapy[NCT05308732] | Phase 1 | 36 participants (Anticipated) | Interventional | 2021-05-11 | Recruiting | ||
| The Effectiveness of Topical Oral Vitamin D Gel in Prevention of Radiation-induced Oral Mucositis[NCT04308161] | Phase 2 | 45 participants (Anticipated) | Interventional | 2019-11-02 | Recruiting | ||
| The Effectiveness of Melatonin in Prevention of Radiation-induced Oral Mucositis[NCT03833570] | Phase 2 | 40 participants (Actual) | Interventional | 2018-01-12 | Completed | ||
| Effect of Prophylactic Use of Oral Vitamin D and Zinc in Management of the Severity of Radiation Induced Oral Mucositis of Head and Neck Cancer Patients[NCT06100692] | 100 participants (Anticipated) | Observational | 2023-11-01 | Not yet recruiting | |||
| An Open-Label, Proof of Concept, Efficacy, Safety and Tolerability Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for the Prevention and Treatment of Oral Mucositis Induced by Radiation Therapy[NCT02399228] | Phase 2 | 13 participants (Actual) | Interventional | 2015-10-04 | Completed | ||
| Phase II, Randomized Study of Concomitant Chemoradiation Using Weekly Carboplatinum/Paclitaxel With (Arm A) or Without (Arm B) Daily Subcutaneous Amifostine in Patients With Newly Diagnosed Locally Advanced Squamous Cell Cancer of the Head and Neck[NCT00095927] | Phase 2 | 58 participants (Actual) | Interventional | 2003-05-31 | Completed | ||
| Impacts of Oral Supplement With L-Glutamine on the Radiation-induced Toxicity and Nutritional Status of Head and Neck Cancer Patients Under Radiotherapy[NCT03015077] | 59 participants (Actual) | Interventional | 2014-07-31 | Completed | |||
| A Phase III Study of Magic Mouthwash Plus Sucralfate Versus Benzydamine HCl for Treatment of Radiation-induced Oral Mucositis in Head and Neck Cancer Patients.[NCT00814359] | Phase 3 | 67 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| "Combined Oncoxin-Viusid® Treatment With Radiotherapy and Chemotherapy in Patients With Head and Neck Cancer. Phase II, Randomized and Double-blind Study"[NCT03541772] | Phase 2 | 60 participants (Actual) | Interventional | 2015-01-20 | Completed | ||
| Normal Tissue Oxygenation Following Radiotherapy[NCT00677040] | 20 participants (Actual) | Observational | 2008-04-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The Radiation Therapy Oncology Group (RTOG) is the measure of anatomical changes associated with oral mucositis. Patients scores will be compared to historical data of patient progression.~RTOG Scoring Criteria- Grade 0(none)- No change over baseline Grade 1(mild)- Irritation, may experience slight pain, not requiring analgesic Grade 2(moderate)- Patchy mucositis that may produce inflammatory serosanguinitis discharge; may experience moderate pain requiring analgesia Grade 3(severe) -Confluent, fibrinous mucositis, may include severe pain requiring narcotic Grade 4(life-threatening)-Ulceration, hemorrhage, or necrosis" (NCT02399228)
Timeframe: Up to ten (10) weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| 0.25% EISO Mouth Rinse | 7 |
"Severity of pain in the oral cavity/oropharynx was measured using the numerical rating pain scale (NRPS) at each study visit. The NRPS is an 11-point scale from 0-10:~0 = No pain 10 = The most intense pain imaginable." (NCT02399228)
Timeframe: Up to ten (10) weeks
| Intervention | score on a scale (Mean) |
|---|---|
| 0.25% EISO Mouth Rinse | 3.875 |
"Adverse Events (AEs) will be assessed in accordance the Common Terminology Criteria for Adverse Events (CTCAE). The number of patients experiencing adverse events possibly, or probably related to the study product will be reported.~Possibly related: A clinical event, including laboratory test abnormality (if applicable), with a reasonable time sequence to administration of the drug, but which could also be explained by concurrent disease or other drugs or chemicals.~Probably related: A clinical event, including laboratory test abnormality (if applicable), with a reasonable time sequence to administration of the drug, unlikely to be attributed to concurrent disease or other drugs or chemicals, and which follows a clinically reasonable response on withdrawal." (NCT02399228)
Timeframe: [ Time Frame: Up to ten (10) weeks ]
| Intervention | participants (Number) | |
|---|---|---|
| Nausea (Mild) | Vomiting (Mild) | |
| 0.25% EISO Mouth Rinse | 2 | 2 |
Transcutaneous oxygen detector is used to measure the partial pressure of oxygen. The unit detects electrolytes ionized by oxygen. The measuring electrode also heats the skin being measured to facilitate maximal bloodflow to the area. (NCT00677040)
Timeframe: One visit for 20 minutes
| Intervention | mmHg (Mean) |
|---|---|
| Subjects | 62.5 |
(NCT00677040)
Timeframe: One visit
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| late subcutaneous toxicitiy score 1 | late subcutaneous toxcity score 2 | late skin toxicity score 1 | late skin toxicity score 2 | |
| Subjects | 19 | 1 | 19 | 1 |
9 reviews available for amifostine anhydrous and Stomatitis
| Article | Year |
|---|---|
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
Mucositis: pathobiology and management.
Topics: Amifostine; Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Fibroblast Growt | 2015 |
Mucositis: pathobiology and management.
Topics: Amifostine; Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Fibroblast Growt | 2015 |
Mucositis: pathobiology and management.
Topics: Amifostine; Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Fibroblast Growt | 2015 |
Mucositis: pathobiology and management.
Topics: Amifostine; Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Fibroblast Growt | 2015 |
Mucositis: pathobiology and management.
Topics: Amifostine; Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Fibroblast Growt | 2015 |
Mucositis: pathobiology and management.
Topics: Amifostine; Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Fibroblast Growt | 2015 |
Mucositis: pathobiology and management.
Topics: Amifostine; Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Fibroblast Growt | 2015 |
Mucositis: pathobiology and management.
Topics: Amifostine; Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Fibroblast Growt | 2015 |
Mucositis: pathobiology and management.
Topics: Amifostine; Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Fibroblast Growt | 2015 |
Strategies for managing radiation-induced mucositis in head and neck cancer.
Topics: Acetylcysteine; Amifostine; Carcinoma, Squamous Cell; Glutamine; Head and Neck Neoplasms; Humans; In | 2009 |
Systematic review of amifostine for the management of oral mucositis in cancer patients.
Topics: Administration, Topical; Amifostine; Evidence-Based Medicine; Humans; Infusions, Intravenous; Inject | 2013 |
Rationale for integrating high-dose rate intraoperative radiation (HDR-IORT) and postoperative external beam radiation with subcutaneous amifostine for the management of stage III/IV head and neck cancer.
Topics: Amifostine; Clinical Trials as Topic; Head and Neck Neoplasms; Humans; Intraoperative Period; Postop | 2003 |
The effect of oral mucositis on morbidity and mortality in bone marrow transplant.
Topics: Amifostine; Bone Marrow Transplantation; Humans; Mouth Mucosa; Radiation-Protective Agents; Risk Fac | 2003 |
Amifostine reduces side effects and improves complete response rate during radiotherapy: results of a meta-analysis.
Topics: Amifostine; Cystitis; Deglutition Disorders; Esophagitis; Humans; Neoplasms; Radiation Injuries; Rad | 2006 |
Amifostine in the management of radiation-induced and chemo-induced mucositis.
Topics: Amifostine; Antineoplastic Agents; Combined Modality Therapy; Esophagitis; Evidence-Based Medicine; | 2006 |
Preventive intervention possibilities in radiotherapy- and chemotherapy-induced oral mucositis: results of meta-analyses.
Topics: Amifostine; Anti-Bacterial Agents; Antineoplastic Agents; Colony-Stimulating Factors; Cranial Irradi | 2006 |
Preventive intervention possibilities in radiotherapy- and chemotherapy-induced oral mucositis: results of meta-analyses.
Topics: Amifostine; Anti-Bacterial Agents; Antineoplastic Agents; Colony-Stimulating Factors; Cranial Irradi | 2006 |
Preventive intervention possibilities in radiotherapy- and chemotherapy-induced oral mucositis: results of meta-analyses.
Topics: Amifostine; Anti-Bacterial Agents; Antineoplastic Agents; Colony-Stimulating Factors; Cranial Irradi | 2006 |
Preventive intervention possibilities in radiotherapy- and chemotherapy-induced oral mucositis: results of meta-analyses.
Topics: Amifostine; Anti-Bacterial Agents; Antineoplastic Agents; Colony-Stimulating Factors; Cranial Irradi | 2006 |
16 trials available for amifostine anhydrous and Stomatitis
| Article | Year |
|---|---|
Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; C | 2009 |
Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Female; Graft Survival; Hum | 2002 |
A pilot study on feasibility and efficacy of amifostine preceding high-dose melphalan with autologous stem cell support in myeloma patients.
Topics: Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Feasibility Studies; Fe | 2002 |
Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients.
Topics: Adult; Aged; Amifostine; Antineoplastic Agents; Carboplatin; Erythrocyte Count; Female; Humans; Infu | 2003 |
Effect of amifostine on toxicities associated with radiochemotherapy in patients with locally advanced non-small-cell lung cancer.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell L | 2003 |
Phase II randomized study of concomitant chemoradiation using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with newly diagnosed locally advanced squamous cell carcinoma of the head and neck.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; C | 2003 |
Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2004 |
A randomized trial of amifostine as a cytoprotectant for patients receiving myeloablative therapy for allogeneic hematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Female; Graft Surviva | 2004 |
Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation.
Topics: Adult; Aged; Amifostine; Cytoprotection; Female; Hematopoietic Stem Cell Transplantation; Humans; Ma | 2005 |
Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study.
Topics: Adult; Aged; Amifostine; Antineoplastic Agents; Carboplatin; Combined Modality Therapy; Disease Prog | 2006 |
[Side effects of postoperative radiochemotherapy with amifostine versus radiochemotherapy alone in head and neck tumors. Preliminary results of a prospective randomized trial].
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Amifostine; Antineoplastic Agents; Carboplatin; Carcinoma, | 1999 |
[Cytoprotection with amifostine in radiotherapy or radio-chemotherapy of head and neck tumors].
Topics: Adult; Aged; Amifostine; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Comb | 1999 |
A randomized study of very accelerated radiotherapy with and without amifostine in head and neck squamous cell carcinoma.
Topics: Adult; Aged; Amifostine; Carcinoma, Squamous Cell; Drug Administration Schedule; Drug Eruptions; Fea | 2000 |
Amifostine can reduce mucosal damage after high-dose melphalan conditioning for peripheral blood progenitor cellautotransplant: a retrospective study.
Topics: Adolescent; Adult; Aged; Amifostine; Analgesics, Opioid; Antineoplastic Agents, Alkylating; Blood Ce | 2000 |
Phase III randomized trial of amifostine as a radioprotector in head and neck cancer.
Topics: Adult; Aged; Amifostine; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Male; Mi | 2000 |
Phase III randomized trial of amifostine as a radioprotector in head and neck cancer.
Topics: Adult; Aged; Amifostine; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Male; Mi | 2000 |
Phase III randomized trial of amifostine as a radioprotector in head and neck cancer.
Topics: Adult; Aged; Amifostine; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Male; Mi | 2000 |
Phase III randomized trial of amifostine as a radioprotector in head and neck cancer.
Topics: Adult; Aged; Amifostine; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Male; Mi | 2000 |
Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer.
Topics: Aged; Amifostine; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Th | 2002 |
16 other studies available for amifostine anhydrous and Stomatitis
| Article | Year |
|---|---|
Amifostine reduces inflammation and protects against 5-fluorouracil-induced oral mucositis and hyposalivation.
Topics: Amifostine; Animals; Cricetinae; Disease Models, Animal; Fluorouracil; Inflammation; Male; Protectiv | 2019 |
Preventing Radiation-Induced Injury by Topical Application of an Amifostine Metabolite-Loaded Thermogel.
Topics: Amifostine; Animals; Blood Pressure; Breast Neoplasms; Disease Models, Animal; DNA Damage; Dogs; Dru | 2019 |
Assessment of the effect of local application of amifostine on acute radiation-induced oral mucositis in guinea pigs.
Topics: Acute Disease; Administration, Topical; Amifostine; Animals; Guinea Pigs; Intercellular Adhesion Mol | 2014 |
Protective effects of amifostine and cyclooxygenase-1 inhibitor against normal human epidermal keratinocyte toxicity induced by methotrexate and 5-fluorouracil.
Topics: Allopurinol; Amifostine; Antimetabolites, Antineoplastic; Calcium; Cell Line; Cell Proliferation; Ce | 2009 |
Differential effect triggered by a heparan mimetic of the RGTA family preventing oral mucositis without tumor protection.
Topics: Amifostine; Animals; Cell Line, Tumor; Drug Administration Schedule; Drug Therapy, Combination; Fema | 2009 |
Cytoprotective effect of amifostine in radiation-induced acute mucositis - a retrospective analysis.
Topics: Acute Disease; Adult; Aged; Amifostine; Esophagus; Female; Gastric Mucosa; Humans; Male; Middle Aged | 2002 |
Subcutaneous administration of amifostine (ethyol) is equivalent to intravenous administration in a rat mucositis model.
Topics: Amifostine; Animals; Female; Injections, Intravenous; Injections, Subcutaneous; Mercaptoethylamines; | 2003 |
Amifostine (ETHYOL) protects rats from mucositis resulting from fractionated or hyperfractionated radiation exposure.
Topics: Amifostine; Animals; Dose Fractionation, Radiation; Drug Evaluation, Preclinical; Female; Injections | 2005 |
Managing oral mucositis in patients with hematologic malignancies.
Topics: Amifostine; Animals; Antineoplastic Agents; Cryotherapy; Fibroblast Growth Factor 7; Hematologic Neo | 2006 |
Chemoradiotherapy for head and neck cancer: 'local' side effects are actually systemic.
Topics: Amifostine; Antineoplastic Agents; Chemotherapy, Adjuvant; Combined Modality Therapy; Deglutition Di | 2006 |
Amelioration of early radiation effects in oral mucosa (mouse) by intravenous or subcutaneous administration of amifostine.
Topics: Amifostine; Animals; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Inject | 2006 |
Daily amifostine given concomitantly to chemoradiation in head and neck cancer. A pilot study.
Topics: Adult; Aged; Amifostine; Carcinoma, Squamous Cell; Cohort Studies; Combined Modality Therapy; Dose F | 1999 |
[New data on cytoprotection in radiotherapy].
Topics: Amifostine; Antineoplastic Agents; Carboplatin; Combined Modality Therapy; Cytoprotection; Double-Bl | 1999 |
[Cytoprotection with amifostine in the framework of radiochemotherapy in previously irradiated head and neck carcinoma].
Topics: Adult; Aged; Amifostine; Anemia; Antineoplastic Agents; Brachytherapy; Carboplatin; Combined Modalit | 1999 |
[Comments on five clinical trials concerning radiotherapy-induced mucositis in patients with head and neck neoplasms].
Topics: Amifostine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Glutamine; Gran | 2001 |
Preclinical modeling of improved amifostine (Ethyol) use in radiation therapy.
Topics: Amifostine; Animals; Female; Head; Injections, Intravenous; Injections, Subcutaneous; Mouth Mucosa; | 2002 |